33,574 Shares in Biogen Inc. $BIIB Acquired by Korea Investment CORP

Korea Investment CORP bought a new stake in Biogen Inc. (NASDAQ:BIIB) during the second quarter, according to its most recent filing with the SEC. The firm bought 33,574 shares of the biotechnology company’s stock, valued at approximately $7,254,000.

A number of other large investors have also made changes to their positions in the stock. Reflection Asset Management bought a new stake in Biogen in the fourth quarter valued at $25,000. Bell Investment Advisors Inc acquired a new position in Biogen during the 2nd quarter worth $27,000. WFA of San Diego LLC bought a new position in Biogen in the second quarter valued at about $32,000. Root Financial Partners LLC boosted its stake in shares of Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 123 shares during the last quarter. Finally, MV Capital Management Inc. acquired a new stake in Biogen during the 4th quarter worth $34,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BIIB shares. Barclays boosted their price target on shares of Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Wednesday, July 29th. Canaccord Genuity Group increased their target price on shares of Biogen from $245.00 to $248.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. UBS Group boosted their price target on Biogen from $225.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Oppenheimer reiterated an “outperform” rating and set a $300.00 price target on shares of Biogen in a report on Wednesday, July 29th. Finally, HSBC reissued a “reduce” rating and issued a $157.00 price objective on shares of Biogen in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Biogen has an average rating of “Moderate Buy” and an average target price of $227.07.

Biogen Stock Up 0.6%

BIIB stock opened at $218.12 on Tuesday. The stock has a market capitalization of $32.23 billion, a P/E ratio of 38.61, a price-to-earnings-growth ratio of 6.75 and a beta of 0.17. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. Biogen Inc. has a 12 month low of $131.52 and a 12 month high of $222.15. The firm has a 50-day moving average price of $205.92 and a 200-day moving average price of $194.87.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating the consensus estimate of $2.94 by $0.66. The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The business’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the company earned $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities research analysts anticipate that Biogen Inc. will post 12.39 EPS for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.